What is the recommended dosage for Moxifloxacin (a fluoroquinolone antibiotic) tablets?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2025 • View editorial policy

From the Guidelines

The recommended dosage for Moxifloxacin tablets is 400 mg taken once daily by mouth. This medication should be taken at the same time each day with or without food, and tablets should be swallowed whole with a full glass of water 1. The typical treatment duration ranges from 5 to 14 days, depending on the type and severity of infection being treated. For respiratory tract infections like pneumonia or sinusitis, treatment usually lasts 7-10 days, while skin infections typically require 7-14 days. Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, which prevents bacteria from replicating their DNA and ultimately kills the infection. It's essential to complete the full course of treatment even if symptoms improve before finishing. Patients should maintain adequate hydration while taking moxifloxacin and should avoid antacids, multivitamins, or products containing magnesium, aluminum, iron, or zinc within 4 hours of taking this medication as these can reduce its effectiveness.

Some key points to consider when prescribing Moxifloxacin include:

  • The medication is effective against a broad spectrum of bacteria, including aerobic and anaerobic organisms 2
  • Moxifloxacin has been shown to be noninferior to other antibiotics, such as ertapenem, in the treatment of complicated intra-abdominal infections 2
  • The medication is generally well-tolerated, with a similar incidence of adverse events compared to other antibiotics 2
  • Moxifloxacin is approved for use in various countries, including Taiwan, for the treatment of intra-abdominal infections, among other indications 2

It's also important to note that the dosage of Moxifloxacin may need to be adjusted in patients with renal or hepatic impairment, and serum drug-concentration monitoring should be considered for dosage individualization 3. Additionally, patients should be advised to seek medical attention if they experience any signs of an allergic reaction or other adverse effects while taking Moxifloxacin.

From the FDA Drug Label

The dose of moxifloxacin is 400 mg (orally) once every 24 hours. Table 1: Dosage and Duration of Therapy in Adult Patients Type of Infectiona Dose Every 24 hours Durationb (days) Community Acquired Pneumonia (1. 1) 400 mg7 to 14 Uncomplicated Skin and Skin Structure Infections (SSSI ) (1.2) 400 mg7 Complicated SSSI (1.3) 400 mg7 to 21 Complicated Intra-Abdominal Infections (1.4) 400 mg5 to 14 Plague (1.5)C 400 mg10 to 14 Acute Bacterial Sinusitis (ABS) (1.6) 400 mg10 Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (1. 7)400 mg5

The recommended dosage for Moxifloxacin tablets is 400 mg taken orally once every 24 hours. The duration of therapy depends on the type of infection, ranging from 5 to 21 days. 4

From the Research

The recommended dosage for Moxifloxacin tablets is as follows:

  • 400 mg once daily, as stated in studies 5, 6, 7, 8, 9 Some key points to consider:
  • Moxifloxacin achieves good penetration into respiratory tissues and fluids 5
  • The bioavailability and half-life of moxifloxacin provides potent bactericidal effects at a dose of 400mg/day 6
  • Moxifloxacin has demonstrated rapid eradication rates and a low potential for drug interactions 6
  • The efficacy and safety profiles of moxifloxacin at the recommended dose of 400 mg daily are characterized in large observational studies 7
  • Sequential moxifloxacin therapy was clinically equivalent to high-dose ceftriaxone +/- erythromycin therapy but led to a faster clinical improvement 8
  • Moxifloxacin monotherapy is as effective and safe as combination therapy with i.v. ceftriaxone plus i.v. metronidazole followed by oral amoxicillin/clavulanate for the treatment of complicated intra-abdominal infections 9

References

Guideline

recommendations and guidelines for the treatment of pneumonia in taiwan.

Journal of Microbiology, Immunology and Infection, 2019

Research

Moxifloxacin in respiratory tract infections.

Expert opinion on pharmacotherapy, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.